173 related articles for article (PubMed ID: 35431054)
1. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):407-412. PubMed ID: 35431054
[TBL] [Abstract][Full Text] [Related]
2. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
4. Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ.
Bartenjev MS; Isaković-Vidović S; Bartenjev I
Acta Dermatovenerol Croat; 2020 Jul; 28(1):34-37. PubMed ID: 32650849
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
6. Topical imiquimod for periocular lentigo maligna.
Demirci H; Shields CL; Bianciotto CG; Shields JA
Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
[TBL] [Abstract][Full Text] [Related]
7. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
[TBL] [Abstract][Full Text] [Related]
8. Periocular lentigo maligna treated with imiquimod.
O'Neill J; Ayers D; Kenealy J
J Dermatolog Treat; 2011 Apr; 22(2):109-12. PubMed ID: 20666668
[TBL] [Abstract][Full Text] [Related]
9. [Lentigo maligna treated with 5% imiquimod cream].
Martín T; Ojeda A; Martínez S; Vera A
Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
Woodmansee CS; McCall MW
Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
[No Abstract] [Full Text] [Related]
11. Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
Neumann I; Patalay R; Kaushik M; Timlin H; Daniel C
Eye (Lond); 2023 Feb; 37(3):408-414. PubMed ID: 35835989
[TBL] [Abstract][Full Text] [Related]
12. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
[TBL] [Abstract][Full Text] [Related]
13. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
Mora AN; Karia PS; Nguyen BM
J Am Acad Dermatol; 2015 Aug; 73(2):205-12. PubMed ID: 26088690
[TBL] [Abstract][Full Text] [Related]
14. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
Powell AM; Russell-Jones R
J Am Acad Dermatol; 2004 May; 50(5):792-6. PubMed ID: 15097969
[TBL] [Abstract][Full Text] [Related]
15. Remission of extensive lentigo maligna after treatment with imiquimod.
Piazza CD; Sampaio SA
An Bras Dermatol; 2009; 84(1):82-4. PubMed ID: 19377765
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lentigo maligna with imiquimod 5% cream.
Hopson B; Richey D; Sajben FP
J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod in the treatment of extensive recurrent lentigo maligna.
Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histologic features associated with lentigo maligna clearance after imiquimod treatment.
Kwak R; Joyce C; Werchniak AE; Lin JY; Tsibris HC
J Dermatolog Treat; 2022 Jun; 33(4):1995-1999. PubMed ID: 34315342
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
20. Five-year recurrence rate of lentigo maligna after off-label treatment with imiquimod.
Cliff SH
Br J Dermatol; 2016 Jan; 174(1):22-3. PubMed ID: 26790655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
